PMGC (ELAB) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
XORTX Therapeutics is the larger company by market cap ($2.7 million vs $2.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELAB | XRTX |
|---|---|---|
| Share price | $3.07 | $1.47 |
| Market cap | $2.49M | $2.66M |
| 1-day change | -1.29% | -20.81% |
| Forward P/E | — | 1.83 |
| EPS (TTM) | $-1,748.36 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2,671.20 | $7.05 |
| 52-week low | $2.59 | $1.46 |
| Distance from 52-week high | -99.89% | -79.22% |
| Average volume | 127.38K | 376.30K |
| Shares outstanding | 809.58K | 1.82M |
| Employees | 32 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PMGC
ELAB stock →PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Health Care · Biotechnology: Pharmaceutical Preparations
ELAB vs XRTX FAQ
Which is bigger, PMGC or XORTX Therapeutics?
XORTX Therapeutics (XRTX) is larger, with a market capitalization of $2.66M compared with $2.49M for PMGC (ELAB).
Are PMGC and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.